Exact Mass: 358.1892
Exact Mass Matches: 358.1892
Found 142 metabolites which its exact mass value is equals to given mass value 358.1892
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
2-(3,7,11-Trimethyldodeca-2,6,10-trienylsulfanyl)benzoic acid
4,4'-Thiobis(6-tert-butyl-m-cresol)
Itopride
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03F - Propulsives > A03FA - Propulsives C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor
Rislenemdaz
Itopride
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03F - Propulsives > A03FA - Propulsives C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor
S-Farnesylthiosalicylic acid;Farnesyl Thiosalicylic Acid;FTS
yohimbinic acid
Yohimbic acid hydrate is an amphoteric demethylated derivative of Yohimbine (HY-12715). Yohimbic acid hydrate exhibits vasodilatory action. Yohimbic acid hydrate also can be used for the research of osteoarthritis (OA)[1][2][3].
Ala Ala Pro Thr
Ala Ala Thr Pro
Ala Pro Ala Thr
Ala Pro Thr Ala
Ala Thr Ala Pro
Ala Thr Pro Ala
Gly Pro Ser Val
Gly Pro Val Ser
Gly Ser Pro Val
Gly Ser Val Pro
Gly Val Pro Ser
Gly Val Ser Pro
Pro Ala Ala Thr
Pro Ala Thr Ala
Pro Gly Ser Val
Pro Gly Val Ser
Pro Ser Gly Val
Pro Ser Val Gly
Pro Thr Ala Ala
Pro Val Gly Ser
Pro Val Ser Gly
Ser Gly Pro Val
Ser Gly Val Pro
Ser Pro Gly Val
Ser Pro Val Gly
Ser Val Gly Pro
Ser Val Pro Gly
Thr Ala Ala Pro
Thr Ala Pro Ala
Thr Pro Ala Ala
Val Gly Pro Ser
Val Gly Ser Pro
Val Pro Gly Ser
Val Pro Ser Gly
Val Ser Gly Pro
Val Ser Pro Gly
Salirasib
D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.
2,2-diphenyl-4-piperidin-1-ylbutanamide,hydrochloride
2-Methyl-2-propanyl 2-benzyl-1,3-dioxo-2,8-diazaspiro[4.5]decane- 8-carboxylate
1-BOC-2-[(2-TRIFLUOROMETHYL-PHENYLAMINO)-METHYL]-PIPERIDINE
1-BOC-2-[(3-TRIFLUOROMETHYL-PHENYLAMINO)-METHYL]-PIPERIDINE
1-BOC-2-[(4-TRIFLUOROMETHYL-PHENYLAMINO)-METHYL]-PIPERIDINE
MK-0657
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent Rislenemdaz (CERC-301) is an orally bioavailable and selective N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM, respectively.
B-[3,5-Difluoro-4-(trans-4-propylcyclohexyl)[1,1-biphenyl]-4-yl]boronic acid
7,8,9,10,18,19,20,21-Octahydro-6H,17H-dibenzo[b,k][1,4,10,13,7,16]tetraoxadiazacyclooctadecine
1,9-Diazaspiro[5.5]undecane, 1-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:1)
5-[(3s)-3-(2-Methoxybiphenyl-4-Yl)but-1-Yn-1-Yl]-6-Methylpyrimidine-2,4-Diamine
5-[(3r)-3-(5-Methoxybiphenyl-3-Yl)but-1-Yn-1-Yl]-6-Methylpyrimidine-2,4-Diamine
N4-[2-(4-phenoxyphenyl)ethyl]-1,2-dihydroquinazoline-4,6-diamine
Ala-Thr-Ala-Pro
A tetrapeptide composed of L-alanine, L-threonine, L-alanine, and L-proline joined in sequence by peptide linkages.
1-butyl-1-methyl-3-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)thiourea
N-[3-(3,4-dihydro-1H-isoquinolin-2-yl)propyl]-[1,2,4]triazolo[4,3-a]quinoxalin-4-amine
5-[(3,4-dimethylphenoxy)methyl]-N-methyl-N-(4-oxanylmethyl)-3-isoxazolecarboxamide
(1R,5S)-7-[4-(2-fluorophenyl)phenyl]-3-(phenylmethyl)-3,6-diazabicyclo[3.1.1]heptane
(1S,5R)-6-[(4-fluorophenyl)methyl]-7-(4-phenylphenyl)-3,6-diazabicyclo[3.1.1]heptane
19-hydroxy-2,3-dinor-6-oxoprostaglandin F1alpha
A prostanoid that is 2,3-dinor-6-oxo-prostaglandin F1alpha in which a hydrogen at position 19 is replaced by a hydroxy group.
(1S,2S,6R,7R)-6-ethyl-1,6-dimethoxyspiro[10-oxa-5-azatricyclo[5.3.1.04,8]undecane-2,3-indole]-2-one
FTIDC
FTIDC is an orally active, noncompetitive, selective allosteric metabotropic glutamate receptor (mGluR) 1 antagonist with an IC50 of 5.8 nM for human mGluR1a. FTIDC has no species differences in its antagonistic activity on recombinant human, mouse, and rat mGluR1[1].
(2r,3r,4r)-4-dodecyl-3-hydroxy-5-oxooxolane-2,3-dicarboxylic acid
4-dodecyl-3-hydroxy-5-oxooxolane-2,3-dicarboxylic acid
(3s,4r,5s,6s,7r)-4,5,6,7-tetrahydroxy-3-(1-hydroxydecyl)-4,5,6,7-tetrahydro-3h-2-benzofuran-1-one
20-hydroxydihydrorankinidine
{"Ingredient_id": "HBIN003409","Ingredient_name": "20-hydroxydihydrorankinidine","Alias": "NA","Ingredient_formula": "C20H26N2O4","Ingredient_Smile": "CCC1(CNC2CC3(C4CC1C2CO4)C5=CC=CC=C5N(C3=O)OC)O","Ingredient_weight": "358.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10009","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101606432","DrugBank_id": "NA"}